Additional file 2: Figure S1. of Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

Nucleotide substitution frequency and context. Figure S2. RRAS2 somatic mutation. Figure S3. Genetic comparison between mucinous ovarian tumors and mucinous cancers from other anatomical sites. Figure S4. ELF3 somatic mutations. Figure S5. H&E stained sections of frozen tissues used for exome discovery cohort. (PDF 9819 kb

Figure S1 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

Varying doses of IFN treatment and PD-L1/IFNAR expression</p

Figure S2 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

The effect of poly(I:C) on immune cell activation</p

Figure S3 from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

The effect of combination treatment on T cell activation</p

Additional file 2: Figure S1. of Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

Nucleotide substitution frequency and context. Figure S2. RRAS2 somatic mutation. Figure S3. Genetic comparison between mucinous ovarian tumors and mucinous cancers from other anatomical sites. Figure S4. ELF3 somatic mutations. Figure S5. H&E stained sections of frozen tissues used for exome discovery cohort. (PDF 9813 kb

Supplementary Figures 1-7 from Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis

Figures S1-S7 Supplementary Figure 1. A2BRi anti-metastatic activity does not require immune cells. Supplementary Figure 2. Mechanism of A2BRi. Supplementary Figure 3. Expression of adenosine receptors in tumor cells. Supplementary Figure 4. Effect of A2BR KD on primary tumor growth. Supplementary Figure 5. ADORA2B expression in human breast cancer. Supplementary Figure 6. A2BRi therapy of human breast cancer xenografts. Supplementary Figure 7. Effect of A2BR KD on cell viability.</p

Supplementary Methods and Figure Legends from Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis

Supplementary Materials and Methods and Supplementary Figure Legends</p

Supplementary Methods from Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Additional information on Materials and Methods including details of antibodies and reagents.</p

Supplementary figure legends from Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

Figure legends for supplementary figures 1, 2 & 3</p

Supplementary Tables and Figures from Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Supplementary Table S1 and Supplementary Figures S1-S3 - Supplementary Table S1: Characteristics of human triple-negative breast cancer cell lines. Supplementary Figure S1: Quantitation of protein expression in HC1806 and MDAMB231 cells following 72 hours of treatment in vitro. Supplementary Figure S2: Combined BYL719 and LEE011 induces anti-tumor immunity in AT3OVA mouse model of triple-negative breast cancer in vivo. Supplementary Figure S3: Immune checkpoint blockade in combination with BYL719 and LEE011 results in durable tumor regression in vivo.</p